Companies › CarThera
1 active drug program in 1 registered trial: 1 Phase 3; Oncology; next expected readout Jan 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SonoCloud-9 (SC9) Ultrasound device to transiently open the blood-brain barrier | – | Phase 3 | Glioblastoma | Jan 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05902169 | SonoCloud-9 (SC9) | Phase 3 | Glioblastoma | Oncology | Jan 2028 |
No annotated target.
–
Verity Pharmaceuticals SecuraBio Fidia Farmaceutici Sumitomo Pharma Switzerland Eleison Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.